Slamon Dennis's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Mar 2, 2022
- Accession no.
- 0001567619-22-006092
- Filed
- Mar 2, 2022
- Trade date
- Feb 28, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market sales total $501.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Slamon DennisCIK 0001603265 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | Common Stock | SSaleDisposed | −5,815 | $78.33 | −$455,488.95 | 22,220 | Direct | |
| Feb 28, 2022 | Common Stock | SSaleDisposed | −45 | $78.34 | −$3,525.3 | 22,175 | Direct | |
| Feb 28, 2022 | Common Stock | SSaleDisposed | −214 | $78.35 | −$16,766.9 | 21,961 | Direct | |
| Feb 28, 2022 | Common Stock | SSaleDisposed | −100 | $78.35 | −$7,835 | 21,861 | Direct | |
| Feb 28, 2022 | Common Stock | SSaleDisposed | −122 | $78.36 | −$9,559.92 | 21,739 | Direct | |
| Feb 28, 2022 | Common Stock | SSaleDisposed | −100 | $78.37 | −$7,837 | 21,639 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.